AI Article Synopsis
- This study investigates how long-term suppression of the renin-angiotensin system and incretin mimetic treatments affect GLP-1 receptor binding in heart tissues of type 1 diabetic rats.
- It involves several treatment groups, including normal rats and those treated with insulin, Exendin-4, Aliskiren, or combinations of these therapies.
- Findings indicate diabetes alters GLP-1 binding affinity in different heart tissues, with Exendin-4 combined with Aliskiren normalizing binding in the coronary endothelium, while Exendin-4 alone is most effective in cardiomyocytes.
Article Abstract
This study focuses on the effects of long-term renin-angiotensin system suppression and/or incretin mimetic therapies on the regulation and binding affinity of GLP-1 to its receptor in the coronary endothelium (CE) and cardiomyocytes (CMs) of type 1 diabetic male Sprague-Dawley rats. The groups assessed are normal (N), streptozotocin-induced diabetic (D), Insulin treated (DI), Exendin-4 treated (DE), Aliskiren treated (DA), cotreated with Insulin and Aliskiren (DIA) and cotreated with exendin-4 and Aliskiren (DEA). Heart perfusion with (125)I-GLP-1 was performed to estimate GLP-1 binding affinity (τ = 1/k-n) to its receptor in the heart. Western Blotting was assessed to determine the expression variation of GLP-1 receptor in the heart. Plasma GLP-1 levels were measured using Enzyme-Linked Immunosorbent Assay (ELISA). Diabetes decreased the τ value on CE and increased it on CMs compared to normal. The combination of Exendin-4 with Aliskiren showed a normalizing effect on the binding affinity of GLP-1 at the coronary endothelium, while at the cardiomyocyte level Exendin-4 treatment alone was the most effective.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124137 | PMC |
| http://dx.doi.org/10.1155/2011/489708 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GLP-1 Agonists in Plastic Surgery: Impact on Aesthetic Outcomes-Two Case Reports.
Aesthetic Plast Surg
January 2025
UOSD Chirurgia Plastica, Dipartimento per la Salute della Donna, del Bambino e di Sanità Pubblica - Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS - Università Cattolica del "Sacro Cuore", Largo A. Gemelli 8, 00168, Rome, Italy.
Background: Obesity is a growing global epidemic, with glucagon-like peptide-1 (GLP-1) receptor agonists emerging as effective pharmacological solutions for weight loss. However, these medications raise concerns in the context of aesthetic and reconstructive surgery due to their effects on wound healing, adipose tissue metabolism, and their potential impact on surgical outcomes.
Objective: To report two cases of delayed wound healing and fat necrosis in patients undergoing breast surgery while receiving GLP-1 receptor agonists for weight management.
Prescription Patterns for GLP-1 Receptor Agonists and SGLT2 Inhibitors by Physicians' Years in Practice.
J Gen Intern Med
January 2025
Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Satiety: a gut-brain-relationship.
J Physiol Sci
January 2025
Psychology department, Faculty of Arts and Sciences, University of Balamand, Balamand, Lebanon.
Many hormones act on the hypothalamus to control hunger and satiety through various pathways closely associated with several factors. When food is present in the gastro intestinal (GI) tract, enteroendocrine cells (EECs) emit satiety signals such as cholecystokinin (CCK), glucagon like peptide-1 (GLP-1) and peptide YY (PYY), which can then communicate with the vagus nerve to control food intake. More specifically, satiety has been shown to be particularly affected by the GLP-1 hormone and its receptor agonists that have lately been acknowledged as a promising way to reduce weight.
View Article and Find Full Text PDFShort- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature.
Endocr J
January 2025
Department of Molecular Diagnosis, Chiba University Graduate school of Medicine, Chiba 260-8670, Japan.
Pasireotide (PAS), a multireceptor somatostatin analog, has been demonstrated to effectively control hormone levels, including those of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), in patients with acromegaly. However, it induces hyperglycemia by inhibiting insulin secretion via somatostatin receptor 5 (SSTR5). Despite the extensive literature on the occurrence of PAS-induced hyperglycemia, there is still no consensus on the optimal first-line treatment for this complication.
View Article and Find Full Text PDFEfficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials.
Diabetes Care
February 2025
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Objective: To provide an updated synthesis on effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on weight, BMI, and waist circumference incorporating newer randomized controlled trials (RCTs), particularly in individuals with overweight or obesity.
Research Design And Methods: We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) for RCTs published from inception to 4 October 2024. The search was limited to RCTs evaluating the use of GLP-1 RAs for mean differences from baseline in weight, BMI, and waist circumference in adults with obesity or overweight with or without diabetes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!